PT  - JOURNAL ARTICLE
AU  - Kathryn E. Kenworthy
AU  - Stephen E. Clarke
AU  - Julie Andrews
AU  - J. Brian Houston
TI  - Multisite Kinetic Models for CYP3A4: Simultaneous Activation and Inhibition of Diazepam and Testosterone Metabolism
DP  - 2001 Dec 01
TA  - Drug Metabolism and Disposition
PG  - 1644--1651
VI  - 29
IP  - 12
4099  - http://dmd.aspetjournals.org/content/29/12/1644.short
4100  - http://dmd.aspetjournals.org/content/29/12/1644.full
SO  - Drug Metab Dispos2001 Dec 01; 29
AB  - Some substrates of cytochrome P450 (CYP) 3A4, the most abundant CYP in the human liver responsible for the metabolism of many structurally diverse therapeutic agents, do not obey classical Michaelis-Menten kinetics and demonstrate homotropic and/or heterotropic cooperativity. The unusual kinetics and differential effects observed between substrates of this enzyme confound the prediction of drug clearance and drug-drug interactions from in vitro data. We have investigated the hypothesis that CYP3A4 may bind multiple molecules simultaneously using diazepam (DZ) and testosterone (TS). Both substrates showed sigmoidal kinetics in B-lymphoblastoid microsomes containing a recombinant human CYP3A4 and reductase. When analyzed in combination, TS activated the formation of 3-hydroxydiazepam (3HDZ) andN-desmethyldiazepam (NDZ) (maximal activation 374 and 205%, respectively). For 3HDZ, Vmax values remained constant with increasing TS, whereas the S50 and Hill values decreased, tending to make the data less sigmoidal. Similar trends were observed for the NDZ pathway. DZ inhibited the formation 6β-hydroxytestosterone (maximal inhibition, 45% of control), causing a decrease in Vmax but no significant change to the S50 and Hill values, suggesting that DZ may inhibit via a separate effector site. Multisite rate equation models have been derived to explore the analysis of such complex kinetic data and to allow accurate determination of the kinetic parameters for activation and inhibition. The data and models presented are consistent with proposals that CYP3A4 can bind and metabolize multiple substrate molecules simultaneously; they also provide a generic solution for the interpretation of the complex kinetic data derived from CYP3A4 substrates. The American Society for Pharmacology and Experimental Therapeutics